SlideShare a Scribd company logo
1 of 41
Hypolipidemic Agents Sachin Kuchya,  MD Assistant Professor, Department of Pharmacology NSCB Medical College, Jabalpur
Why do we need them? ,[object Object],[object Object],[object Object]
Overview of Presentation  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
GLOSSARY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PHYSIOLOGY Enterohepatic circulation  - Bile acids CHL Pool Dietary CHL  De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL ,[object Object],[object Object],[object Object],[object Object],To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP Tightly regulated  Diurnal variation
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Non Pharmacological & Pharmacological targets 1 2 3 4 5 6 7 Dietary Atheroma HDL2  CHL Pool CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL Gut  HDL3  CHL ester TG  LDL CETP Bile acids
Statins – effect on lipids ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – additional effects ,[object Object],[object Object],[object Object],[object Object]
Statins – Clinical Pharmacokinetics ,[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – adverse effects  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – indications ,[object Object],[object Object]
Bile acid binding resins ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bile acid binding resins – adverse effects ,[object Object],[object Object],[object Object],[object Object],[object Object]
Bile acid binding resins ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ezetimibe ,[object Object],[object Object],[object Object],[object Object]
Ezetimibe  ,[object Object],[object Object],[object Object]
Niacin  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Physiologic dose, as vitamin B3– 50mg/ day Pharmacologic dose, as hypolipidemic agent –  2 – 6gm/day.
Niacin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Niacin - indications ,[object Object],[object Object],[object Object]
Fibric acid derivatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fibric acid derivatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fibric acid  - indications ,[object Object],[object Object],[object Object]
CETP inhibitor - Torcetrapib ,[object Object],[object Object]
ω3 – fatty acids ,[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical states  ,[object Object],[object Object]
Chylomicronemia  Dietary restriction  1 Clinical state - 1 CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 1 Bile acids
Hypercholesterolemia 2 5 4 3 Cholesterol absorption inhibitor Bile acid binding resin HMG CoA reductase inhibitor VLDL secretion inhibitor Clinical state - 2 CHL Pool Dietary CHL  De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 2 5 3 4 Bile acids
CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL atheroma Gut  HDL2  HDL3  CHL ester TG  LDL CETP 6 5 Hypertriglyceridemia  6 5 VLDL secretion inhibitor Fibric acid derivatives Clinical state - 3
Low HDL-c levels VLDL secretion inhibitor CETP inhibitor 5 7 Clinical state - 4 CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL Atheroma  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 7 5
Special Population ,[object Object],[object Object]
Special population – Children ,[object Object],[object Object],[object Object],[object Object]
Special population – Children ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Women ,[object Object],[object Object],[object Object]
Combination regimens – why? ,[object Object],[object Object],[object Object],[object Object]
Combination regimens – when? ,[object Object],[object Object],[object Object]
LDL-c reduction ,[object Object],[object Object],[object Object]
VLDL reduction ,[object Object],[object Object]
Minimize doses and side effects ,[object Object]
Diabetic patient ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetic patient - drugs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you  Topic is open for queries

More Related Content

What's hot

Pharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsPharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsDr. Advaitha MV
 
Drugs used in Congestive heart failure
Drugs used in Congestive heart failure Drugs used in Congestive heart failure
Drugs used in Congestive heart failure shoaib241087
 
Coagulants and anticoagulants
Coagulants and anticoagulantsCoagulants and anticoagulants
Coagulants and anticoagulantsAnkita Bist
 
Antihyperlipidemic drugs rahul sharma
Antihyperlipidemic drugs rahul sharmaAntihyperlipidemic drugs rahul sharma
Antihyperlipidemic drugs rahul sharmarahulsharma3589
 
Antihyperlipidemics1
Antihyperlipidemics1Antihyperlipidemics1
Antihyperlipidemics1Dr Shah Murad
 
Antiplatelets and anticoagulants
Antiplatelets and anticoagulantsAntiplatelets and anticoagulants
Antiplatelets and anticoagulantsEdson Mutandwa
 
Oral hypoglycaemic agents 2020
Oral hypoglycaemic agents 2020Oral hypoglycaemic agents 2020
Oral hypoglycaemic agents 2020Pravin Prasad
 
Pharmacotherapy of arrhythmia
Pharmacotherapy of arrhythmiaPharmacotherapy of arrhythmia
Pharmacotherapy of arrhythmiaPravin Prasad
 
Hyperlipidemia, pharmacology
Hyperlipidemia, pharmacologyHyperlipidemia, pharmacology
Hyperlipidemia, pharmacologyMohd Siraj
 
lipid-lowering drugs
lipid-lowering drugslipid-lowering drugs
lipid-lowering drugsElham Khaled
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failureNaser Tadvi
 

What's hot (20)

Pharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsPharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugs
 
Heparin
HeparinHeparin
Heparin
 
Drugs used in Congestive heart failure
Drugs used in Congestive heart failure Drugs used in Congestive heart failure
Drugs used in Congestive heart failure
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Coagulants and anticoagulants
Coagulants and anticoagulantsCoagulants and anticoagulants
Coagulants and anticoagulants
 
Antihyperlipidemic drugs rahul sharma
Antihyperlipidemic drugs rahul sharmaAntihyperlipidemic drugs rahul sharma
Antihyperlipidemic drugs rahul sharma
 
Pharmacotherapy of dyslipidemia
Pharmacotherapy of dyslipidemiaPharmacotherapy of dyslipidemia
Pharmacotherapy of dyslipidemia
 
Antihyperlipidemics1
Antihyperlipidemics1Antihyperlipidemics1
Antihyperlipidemics1
 
Antiplatelets and anticoagulants
Antiplatelets and anticoagulantsAntiplatelets and anticoagulants
Antiplatelets and anticoagulants
 
Heparin
HeparinHeparin
Heparin
 
Oral hypoglycaemic agents 2020
Oral hypoglycaemic agents 2020Oral hypoglycaemic agents 2020
Oral hypoglycaemic agents 2020
 
Pharmacotherapy of arrhythmia
Pharmacotherapy of arrhythmiaPharmacotherapy of arrhythmia
Pharmacotherapy of arrhythmia
 
Thrombolytics or Fibrinolytics
Thrombolytics or FibrinolyticsThrombolytics or Fibrinolytics
Thrombolytics or Fibrinolytics
 
Hyperlipidemia, pharmacology
Hyperlipidemia, pharmacologyHyperlipidemia, pharmacology
Hyperlipidemia, pharmacology
 
lipid-lowering drugs
lipid-lowering drugslipid-lowering drugs
lipid-lowering drugs
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failure
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Heparin
HeparinHeparin
Heparin
 
Statins
StatinsStatins
Statins
 
ACE inhibitors drugs
ACE inhibitors drugsACE inhibitors drugs
ACE inhibitors drugs
 

Similar to Hypolipidemic agents

Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints HypolipidemicsMD Specialclass
 
Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints HypolipidemicsMD Specialclass
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of HyperlipidemiaHealth Forager
 
Hypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxHypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxKiran Piparva
 
Antilipemics
AntilipemicsAntilipemics
Antilipemicsraj kumar
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugsajaykumarbp
 
Antihyperlipidemics2
Antihyperlipidemics2Antihyperlipidemics2
Antihyperlipidemics2Dr Shah Murad
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxMohammedObaidMohiudd
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic DrugsDinesh Kumar
 
Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaIndian Health Journal
 
Class hypolipidemics
Class hypolipidemicsClass hypolipidemics
Class hypolipidemicsRaghu Prasada
 
Class hypolipidemics
Class hypolipidemics Class hypolipidemics
Class hypolipidemics Raghu Prasada
 
Pharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsPharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsKoppala RVS Chaitanya
 

Similar to Hypolipidemic agents (20)

Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints Hypolipidemics
 
Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints Hypolipidemics
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
 
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptxhyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
 
Hypolipidaemic drugs
Hypolipidaemic drugsHypolipidaemic drugs
Hypolipidaemic drugs
 
Dyslipidemia approach
Dyslipidemia approachDyslipidemia approach
Dyslipidemia approach
 
Hypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxHypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptx
 
Antilipemics
AntilipemicsAntilipemics
Antilipemics
 
Lipid modifying drug dr. tariqul
Lipid modifying drug  dr. tariqulLipid modifying drug  dr. tariqul
Lipid modifying drug dr. tariqul
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Antihyperlipidemics2
Antihyperlipidemics2Antihyperlipidemics2
Antihyperlipidemics2
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptx
 
Anti dyslipidemic agents
Anti dyslipidemic agentsAnti dyslipidemic agents
Anti dyslipidemic agents
 
Hyperlipidemia
Hyperlipidemia Hyperlipidemia
Hyperlipidemia
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic Drugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay Kantharia
 
Class hypolipidemics
Class hypolipidemicsClass hypolipidemics
Class hypolipidemics
 
Class hypolipidemics
Class hypolipidemics Class hypolipidemics
Class hypolipidemics
 
Pharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsPharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugs
 

Hypolipidemic agents

  • 1. Hypolipidemic Agents Sachin Kuchya, MD Assistant Professor, Department of Pharmacology NSCB Medical College, Jabalpur
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26. Chylomicronemia Dietary restriction 1 Clinical state - 1 CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL To various body tissues, Gut HDL2 HDL3 CHL ester TG LDL CETP 1 Bile acids
  • 27. Hypercholesterolemia 2 5 4 3 Cholesterol absorption inhibitor Bile acid binding resin HMG CoA reductase inhibitor VLDL secretion inhibitor Clinical state - 2 CHL Pool Dietary CHL De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50% 50% VLDL LDL TG CHL To various body tissues, Gut HDL2 HDL3 CHL ester TG LDL CETP 2 5 3 4 Bile acids
  • 28. CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL atheroma Gut HDL2 HDL3 CHL ester TG LDL CETP 6 5 Hypertriglyceridemia 6 5 VLDL secretion inhibitor Fibric acid derivatives Clinical state - 3
  • 29. Low HDL-c levels VLDL secretion inhibitor CETP inhibitor 5 7 Clinical state - 4 CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL Atheroma Gut HDL2 HDL3 CHL ester TG LDL CETP 7 5
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41. Thank you Topic is open for queries